Pacira (PCRX) — Buy the Disconnect; Generic Threats Look Priced for Immediate Risk
Pacira is a specialty pain-management business trading at a sub-$1B market cap with robust free cash flow and a concentrated, durable product franchise. Recent Paragraph IV litigation headlines and a securities suit have pushed sentiment and elevated short interest, but the commercial moat and cash generation argue for a long trade while the legal …